Literature DB >> 27365214

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.

C M Nijenhuis1, A D R Huitema1, C Blank2, J B A G Haanen2, J V van Thienen2, H Rosing1, J H M Schellens3,4, J H Beijnen1,4.   

Abstract

Entities:  

Keywords:  LC-MS/MS; exposure-response; pharmacokinetics; routine clinical care; therapeutic drug monitoring; vemurafenib

Mesh：

Substances：

Year:  2016        PMID： 27365214     DOI： 10.1002/jcph.788

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  6 in total

Review 1.  Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine.

Authors:  Stefanie L Groenland; Ron H J Mathijssen; Jos H Beijnen; Alwin D R Huitema; Neeltje Steeghs
Journal:  Eur J Clin Pharmacol       Date:  2019-06-07       Impact factor: 2.953

2.  Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.

Authors:  Fanny Garlan; Benoit Blanchet; Nora Kramkimel; Alicja Puszkiel; Jean-Louis Golmard; Gaelle Noe; Nicolas Dupin; Pierre Laurent-Puig; Michel Vidal; Valerie Taly; Audrey Thomas-Schoemann
Journal:  Target Oncol       Date:  2017-06       Impact factor: 4.493

Review 3.  Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.

Authors:  Remy B Verheijen; Huixin Yu; Jan H M Schellens; Jos H Beijnen; Neeltje Steeghs; Alwin D R Huitema
Journal:  Clin Pharmacol Ther       Date:  2017-09-07       Impact factor: 6.875

Review 4.  Therapeutic drug monitoring of oral targeted antineoplastic drugs.

Authors:  Anna Mueller-Schoell; Stefanie L Groenland; Oliver Scherf-Clavel; Madelé van Dyk; Wilhelm Huisinga; Robin Michelet; Ulrich Jaehde; Neeltje Steeghs; Alwin D R Huitema; Charlotte Kloft
Journal:  Eur J Clin Pharmacol       Date:  2020-11-09       Impact factor: 2.953

Review 5.  Targeting the "undruggable" RAS - new strategies - new hope?

Authors:  Britta Mörchen; Oleksandr Shkura; Raphael Stoll; Iris Helfrich
Journal:  Cancer Drug Resist       Date:  2019-09-19

6.  The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study.

Authors:  Lotte M Knapen; Rutger H T Koornstra; Johanna H M Driessen; Bas van Vlijmen; Sander Croes; Stein Schalkwijk; Angela Colbers; Winald R Gerritsen; David M Burger; Frank de Vries; Nielka P van Erp
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.